Lifeline creates subsidiary for breast cancer test
This article was originally published in Clinica
Executive Summary
Reno, Nevada-based Lifeline Biotechnologies has formed a new subsidiary which will focus its efforts on the commercialisation of the firm’s First Warning breast cancer detection system. The creation of the new unit, which will be named First Warning Systems, was prompted when Lifeline filed for patent approval for the technology. The non-imaging system is designed to detect the disease at an early stage by classifying time-related circadian pattern changes in new blood cells supplying a breast cancer. Lifeline claims that the system “records information every five minutes for the duration of the test, collecting over 9,000 data points. The data are then subjected to non-linear algorithmic computer analysis designed to identify abnormalities or disruptions in the normal breast physiology”.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals